Laura Iadeluca

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

Benjamin Solomon, Todd M. Bauer, Tony Mok et al. · The Lancet Respiratory Medicine · 2022 · 221 citations

Medicine, Oncology, Pharmacology +10

The burden of family caregiving in the United States: work productivity, health care resource utilization, and mental health among employed adults

Markay Hopps, Laura Iadeluca, Margaret V. McDonald et al. · Journal of Multidisciplinary Healthcare · 2017 · 128 citations · Full text

Medicine, Health Behavior, Behavioral Health +14

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

Julien Mazières, Laura Iadeluca, Alice T. Shaw et al. · Lung Cancer · 2022 · 48 citations · Full text

Medicine, Oncology, Pharmacology +13

The burden of selected cancers in the US: health behaviors and health care resource utilization

Laura Iadeluca, Jack Mardekian, Pratibha Chander et al. · Cancer Management and Research · 2017 · 47 citations · Full text

Medicine, Health Behavior, Oncology +15

Effectiveness of crizotinib versus entrectinib in <i>ROS1</i> -positive non-small-cell lung cancer using clinical and real-world data

Gabriel Tremblay, M Groff, Laura Iadeluca et al. · Future Oncology · 2022 · 22 citations · Full text

Medicine, Oncology, Pharmacology +17